Detalhe da pesquisa
1.
The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.
Hum Psychopharmacol;
36(1): 1-11, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32976677
2.
Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial.
Br J Psychiatry;
208(1): 78-86, 2016 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25999335
3.
How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine.
CNS Spectr;
20(1): 29-38, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24330826
4.
Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial.
Int J Neuropsychopharmacol;
16(10): 2219-34, 2013 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23823799
5.
Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France.
Clin Drug Investig;
40(11): 1009-1020, 2020 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32729068
6.
The DSM-IV-based Generalized Anxiety Disorder Severity Scale: preliminary validation using data from a trial of agomelatine versus placebo.
J Nerv Ment Dis;
197(6): 391-4, 2009 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19525737
7.
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
J Clin Psychopharmacol;
28(5): 561-6, 2008 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18794654
8.
Effect of agomelatine 25-50â¯mg on functional outcomes in patients with major depressive disorder.
J Affect Disord;
238: 122-128, 2018 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29879606
9.
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50â¯mg/day) versus escitalopram (10-20â¯mg/day) in out-patients with severe generalized anxiety disorder.
Eur Neuropsychopharmacol;
28(8): 970-979, 2018 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30135032
10.
Antidepressant effect in older depressed patients: the lessons of two agomelatine trials.
Int Clin Psychopharmacol;
32(4): 184-194, 2017 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28383308
11.
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
Eur Neuropsychopharmacol;
27(5): 526-537, 2017 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28298261
12.
Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.
Eur Neuropsychopharmacol;
26(2): 378-389, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26708320
13.
[Development of a new antidepressant : agomelatine]. / Comment développer un antidépresseur au mécanisme d'action innovant: l'exemple de l'agomélatine.
Med Sci (Paris);
21(10): 888-93, 2005 Oct.
Artigo
em Francês
| MEDLINE
| ID: mdl-16197911
14.
A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
Eur Neuropsychopharmacol;
24(4): 553-63, 2014 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24530273
15.
Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine.
Int Clin Psychopharmacol;
28(1): 20-8, 2013 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23151774
16.
Agomelatine facilitates positive versus negative affective processing in healthy volunteer models.
J Psychopharmacol;
25(9): 1159-67, 2011 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20660010
17.
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
Nat Rev Drug Discov;
9(8): 628-42, 2010 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20577266